Incomplete 5-FU based adjuvant chemotherapy in patients with stage III colon cancer significantly prolongs overall survival

Although our study was not randomized we were able to show a highly statistically significant survival advantage of incomplete adjuvant chemotherapy in patients with UICC stage III colon cancer. If side effects of chemotherapy are tolerable for the patient, temporary limitations of the individual quality of life are outweighed by the survival advantage even if therapy is not completed.